Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC increased its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 54.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,979,847 shares of the company’s stock after buying an additional 694,385 shares during the quarter. Geode Capital Management LLC owned about 1.23% of Neumora Therapeutics worth $26,159,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Bank of New York Mellon Corp lifted its holdings in Neumora Therapeutics by 474.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 235,593 shares of the company’s stock valued at $2,316,000 after acquiring an additional 194,559 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in Neumora Therapeutics during the second quarter valued at approximately $166,000. Rhumbline Advisers boosted its holdings in Neumora Therapeutics by 488.3% during the second quarter. Rhumbline Advisers now owns 103,258 shares of the company’s stock worth $1,015,000 after buying an additional 85,706 shares in the last quarter. TD Asset Management Inc boosted its holdings in Neumora Therapeutics by 31.6% during the second quarter. TD Asset Management Inc now owns 144,994 shares of the company’s stock worth $1,425,000 after buying an additional 34,800 shares in the last quarter. Finally, Amalgamated Bank grew its position in Neumora Therapeutics by 472.8% in the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after buying an additional 2,402 shares during the last quarter. Institutional investors own 47.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on NMRA shares. Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research note on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Neumora Therapeutics in a research note on Monday, December 16th. Royal Bank of Canada restated an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a report on Friday, November 22nd. Finally, JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.40.

Insider Activity

In related news, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the transaction, the director now directly owns 20,100 shares in the company, valued at $342,303. The trade was a 41.14 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Robert A. Lenz sold 5,563 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total value of $83,500.63. Following the sale, the insider now owns 322,966 shares in the company, valued at approximately $4,847,719.66. This represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.40% of the stock is owned by company insiders.

Neumora Therapeutics Trading Up 6.7 %

NMRA opened at $11.34 on Friday. The stock has a fifty day moving average price of $11.18 and a 200 day moving average price of $11.56. Neumora Therapeutics, Inc. has a 1 year low of $8.33 and a 1 year high of $21.00. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -6.06 and a beta of 3.34.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period in the prior year, the business earned ($1.14) earnings per share. As a group, sell-side analysts forecast that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.